West Oak Capital LLC Has $601,000 Stock Position in Pfizer Inc. (NYSE:PFE)

West Oak Capital LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,950 shares of the biopharmaceutical company’s stock after buying an additional 2,564 shares during the period. West Oak Capital LLC’s holdings in Pfizer were worth $601,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Worth Asset Management LLC bought a new stake in Pfizer in the 1st quarter valued at about $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. bought a new position in shares of Pfizer during the fourth quarter valued at about $50,000. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC grew its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Friday, March 1st. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Barclays lowered their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Up 0.3 %

Shares of NYSE PFE traded up $0.09 during midday trading on Thursday, reaching $27.87. 8,958,670 shares of the stock were exchanged, compared to its average volume of 43,314,059. The business has a 50-day simple moving average of $27.47 and a two-hundred day simple moving average of $29.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market capitalization of $157.81 billion, a price-to-earnings ratio of 77.47, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.